Investment
Features
FeesSafety
Academy
More
Pluang+

Compare RLX Technology Inc (RLX) vs Smith & Nephew plc (SNN) Price & Performance

RLX Technology IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

RLX Technology Inc vs Smith & Nephew plc — how do they compare? RLX Technology Inc trades at $2.02 (market cap $2.42B), while Smith & Nephew plc trades at $29.82 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 5.2× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.05%). Which is the better fit depends on your goals.

RLXSNN
Market Cap
$2.42B$12.54B
Sector
TechnologyHealth
52-Week High
$2.73$38.70
52-Week Low
$1.79$28.73
Enterprise Value
$1.04B$15.57B
Dividend Yield
5.05%2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

RLX Technology Inc

RLX Technology trades at $2.02, up 1.0% with bearish technical signals despite recent earnings misses. The company maintains strong profitability with 22.47% net margins and international expansion driving revenue growth from $3.62B to $4.4B. Cash flow trends show operational strength but negative net cash flow. Analyst coverage remains limited with a single hold rating.

RLX faces execution risks from international integration while trading at reasonable valuations (P/E 17.96). The upcoming Q2 2026 earnings on August 14 will be crucial for validating growth trajectory amid competitive and regulatory pressures in the global e-vapor market.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.

While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.

Returns comparison

Trailing returns across standard periods

About RLX Technology Inc

RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.

Read more on RLX

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN